Black Peter C, Brown Gordon A, Dinney Colin P N
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Expert Rev Anticancer Ther. 2007 Jul;7(7):1015-26. doi: 10.1586/14737140.7.7.1015.
Pure urothelial carcinoma makes up 90-95% of all bladder cancer. The remaining 5-10% represent urothelial carcinoma with aberrant differentiation patterns and nonurothelial carcinoma. Reviews on this topic often focus on the pathological features of these histologic subtypes. In this review we have summarized the clinical significance of each major histologic pattern and analyzed the response of each to standard treatment modalities. The main limitation to optimizing management is the inability to perform clinical trials owing to the rarity of these tumors. This can be circumvented to some degree by extrapolating knowledge acquired from more common similar tumors in other organ sites. Ultimately, however, multicenter clinical trials will need to be organized to address some key management issues.
纯尿路上皮癌占所有膀胱癌的90 - 95%。其余5 - 10%为具有异常分化模式的尿路上皮癌和非尿路上皮癌。关于该主题的综述通常聚焦于这些组织学亚型的病理特征。在本综述中，我们总结了每种主要组织学模式的临床意义，并分析了每种模式对标准治疗方式的反应。优化管理的主要限制在于由于这些肿瘤罕见而无法开展临床试验。通过推断从其他器官部位更常见的相似肿瘤中获得的知识，这一限制在一定程度上可以得到规避。然而，最终需要组织多中心临床试验来解决一些关键的管理问题。
